^
BIOMARKER:

HRAS mutation

i
Other names: HRAS, HRAS1, Harvey rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
HRAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
HRAS mutation
SCCHN
tipifarnib
Sensitive: B - Late Trials
HRAS mutation
Urothelial Cancer
tipifarnib
Sensitive: C2 – Inclusion Criteria
HRAS mutation
Thyroid Gland Carcinoma
trametinib
Sensitive: C2 – Inclusion Criteria
HRAS mutation
Multiple Myeloma
selinexor
Sensitive: C3 – Early Trials
HRAS mutation
AML
venetoclax
Sensitive: C3 – Early Trials
HRAS mutation
CRC
sorafenib
Sensitive: C3 – Early Trials
HRAS mutation
CRC
EGFR inhibitor
Sensitive: C3 – Early Trials
HRAS mutation
AML
venetoclax + ABBV-621
Sensitive: C3 – Early Trials
HRAS mutation
Salivary Gland Cancer
tipifarnib
Sensitive: C3 – Early Trials
HRAS mutation
SCCHN
cetuximab
Resistant: C3 – Early Trials
HRAS mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
HRAS mutation
Solid Tumor
selumetinib
Resistant: C3 – Early Trials
HRAS mutation
CRC
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
HRAS mutation
Melanoma
cobimetinib + HM95573
Sensitive: C3 – Early Trials
HRAS mutation
AML
mTOR inhibitor
Resistant: D – Preclinical
HRAS mutation
Rhabdomyosarcoma
tipifarnib
Sensitive: D – Preclinical
HRAS mutation
Endometrial Cancer
AZ 628
Sensitive: D – Preclinical
HRAS mutation
Endometrial Cancer
PD-0325901
Sensitive: D – Preclinical
HRAS mutation
Bladder Cancer
FL118
Sensitive: D – Preclinical